Literature DB >> 2449146

Evaluation of chronic urethritis. Defining the role for endoscopic procedures.

J N Krieger1, T M Hooton, P J Brust, K K Holmes, W E Stamm.   

Abstract

We determined the prevalence of structural and functional abnormalities of the lower urinary tract in a carefully defined population of 36 men with chronic urethritis who were attending a sexually transmitted disease clinic. They had experienced symptoms for an average of 12.1 months and had been treated with an average of 5.1 courses of antimicrobial drugs. All had objective evidence of urethral inflammation and negative cultures for both Neisseria gonorrhoeae and Chlamydia trachomatis. Structural abnormalities were documented in nine (25%) of 36 patients but were considered clinically significant in only four. Physical examination and uroflow testing led to clinical suspicion of anatomic abnormalities in all four patients with significant lesions, which included urethral strictures in three patients and benign prostatic hypertrophy in one patient. Additional abnormal findings included wide-bore strictures in three patients and developmental abnormalities of doubtful significance in two patients. Increased numbers of inflammatory cells in expressed prostatic secretions were associated with the presence of structural abnormalities. We conclude that among men with chronic urethritis, careful physical examination and uroflow studies can be used to screen for evidence of structural abnormalities that merit endoscopic evaluation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449146

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

Review 1.  Effective treatment of urethritis. A practical guide.

Authors:  W R Bowie
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

2.  Atypical genital herpes: report of five cases.

Authors:  Anneli Uusküla; Elve Raukas
Journal:  Scand J Infect Dis       Date:  2004

Review 3.  Management of non-gonococcal urethritis.

Authors:  Harald Moi; Karla Blee; Patrick J Horner
Journal:  BMC Infect Dis       Date:  2015-07-29       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.